India Pharma Outlook Team | Wednesday, 19 March 2025
The main SGLT2 inhibitor Xenia (empagliflozin and its combos) was introduced by USV, an Indian global healthcare business, to treat type 2 diabetes patients' heart failure, chronic renal disease, and glycaemic management. With this introduction, USV reaffirms its leadership in oral anti-diabetes therapy and increases its market share in the Rs. 1,100 crore SGLT2i market.
USV has introduced Xenia (empagliflozin 10 mg & 25 mg), Xenia M (empagliflozin 12.5 mg + metformin 500 mg IR/1000 mg ER), and Xenia ST (empagliflozin 25 mg + sitagliptin 100 mg).
In order to lower diabetic complications and mortality, these combinations provide variable dosage, less pill load, and better access to contemporary treatments.
"India has over 101 million people with type 2 diabetes and 136 million with prediabetes. With Xenia, we aim to expand access to modern diabetes care while reinforcing our leadership in the segment. USV remains committed to delivering affordable, high-quality therapies for better patient outcomes." Prashant Tewari, managing director, USV said.
Empagliflozin and its combinations are now one-fifth the price due to the loss of exclusivity, which improves affordability. Xenia's accessibility throughout the country, including rural locations, is guaranteed by USV's strong reach across corporate hospitals, e-pharmacies, Tier I, II, and III cities, and metro areas.
USV Private Limited, a prominent Indian global healthcare corporation with operations in more than 65 countries, was founded in 1961. In India, USV is the most prescribed oral anti-diabetic and cardiac medication. APIs, generics, branded generics, peptides, and biosimilars are all part of its global portfolio.
, CDSCO.jpg)
